CGM Prescription Rates Low at Federally Qualified Health Centers
CGM prescription rates were low at federally qualified health centers, especially among patients without insurance and non-White patients.
Related Articles
Advocacy in Action
The Endocrine Society examines the recent release of the LHHS Appropriations Subcommittee bill as well as the CMS proposed physician fee schedule rule for FY24.
Nephrotic Syndrome as a Complication of Systemic Calcitonin Amyloidosis From Long-Standing Metastatic Medullary Thyroid Cancer
Medullary thyroid cancer often results in elevated calcitonin levels, which can cause localized formation of calcitonin amyloid, though rarely complications of systemic calcitonin amyloidosis have…
On-Demand Education – The Obesity Society
On-Demand Education: Science from The Obesity Society The Obesity Society (TOS) on-demand education is a great way to gain an in-depth understanding of essential aspects…
Hospital Discharge After MI Marks Opportunity to Increase Medication Use in T2D
Hospital discharge after MI was associated with longer-term medication use among those with T2D who were already using said medications.
Fighting for Fairness 2025 | American Diabetes Association
Join the Legal Advocacy Division of the American Diabetes Association at our Fighting for Fairness webinar series beginning in early 2025. Fighting for Fairness consists…
Grassroots Advocacy | ADA
Learn how to get involved today! Grassroots advocacy for the ADA helps improve the lives of those living with diabetes.
ESE Clinical Update on Aggressive Pituitary Tumours – 24- 26 March 2025
The ESE Clinical Update on Aggressive Pituitary Tumours 2025 will take place online from Monday 24 March 2025 – Wednesday 26 March 2025.
Hybrid Closed Loop Technology Outperforms Standard Insulin in T1D
Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events.
The promise and hope of GLP-1 receptor agonists
GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits…